Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic ...

Investing.com -- AstraZeneca PLC (ST:AZN) stock fell 1.5% in Tuesday morning trade after the U.S. Food and Drug ...

OPKO Health, Inc. (NASDAQ: OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO), and Entera Bio Ltd. (NASDAQ: ENTX) (Entera or the Company), a leader in the development of oral peptide and ...

Halozyme (HALO) outlook: acquisitions extend IP beyond 2027, royalties are set to top $1B in 2026, and shares look discounted ...

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed ...

February 2026 Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus The US Food and Drug Administration (FDA) issued a complete response letter (CRL) ...

This is the third program that successfully combines Entera's oral peptide N-Tab- platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to ...

On 14 July 2025, the World Health Organization (WHO) issued new guidelines recommending twice-yearly injectable lenacapavir as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention.

Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.

Merck & Co., Inc. (NYSE:MRK) Q4 2025 Earnings Call Transcript February 3, 2026 Merck & Co., Inc. beats earnings expectations.

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...